Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 19 Jul 2021 |
| Orion Corporation's financial reporting and Annual General Meeting in 2022 | 19 Jul 2021 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 16 Jul 2021 |
| Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) | 15 Jul 2021 |
| 32,884 Orion Corporation A shares converted into B shares | 8 Jul 2021 |